Real-life Effectiveness of Afatinib Versus Gefitinib in
Patients With Non-small-cell Lung Cancer: A Czech Multicentre
Study

J 2021

Real-life Effectiveness of Afatinib Versus Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study

SVATON, Martin; Monika BRATOVÁ; Ondrej FISCHER; Jana KREJCI; Leona KOUBKOVA et al.

Základní údaje

Originální název

Real-life Effectiveness of Afatinib Versus Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study

Autoři

Vydání

Anticancer Research, Athens, International Institute of Anticancer Research, 2021, 0250-7005

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Řecko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.435

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/21:00121675

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Afatinib; gefitinib; NSCLC; real world data

Štítky

14110215, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 31. 5. 2021 08:49, Mgr. Tereza Miškechová

Anotace

V originále

Background/Aim: We investigated efficacy differences for afatinib versus gefitinib in non-small-cell lung cancer (NSCLC) according to epidermal growth factor receptor (EGFR) mutations. Patients and Methods: We retrospectively analysed data for 343 patients with NSCLC with performance status 1 having EGFR mutations treated with gefitinib or afatinib. Overall response rate (ORR) was tested by Fisher & rsquo;s exact test. Overall (OS) and progression free (PFS) survival were estimated by Kaplan & ndash;Meier method. Results: ORR did not differ in any group or subgroup. Among all patients, we observed significantly longer PFS for those treated with afatinib vs. gefitinib (median 13.4 vs. 9.5 months, p=0.026), but only a nonsignificant trend was observed for OS. We showed nonsignificant trends of better PFS and OS using afatinib for exon 19 deletion and L858R subgroups. We observed no significant PFS differences for other EGFR mutations but a nonsignificant trend towards better OS for those treated with afatinib. Conclusion: Afatinib led to longer PFS for patients with common EGFR mutations but not for those with rare mutations.

Citovat

SVATON, Martin; Monika BRATOVÁ; Ondrej FISCHER; Jana KREJCI; Leona KOUBKOVA; Marketa CERNOVSKA; Michal HRNCIARIK; Milada ZEMANOVA; Helena ČOUPKOVÁ; Bedrich PORZER; Daniel DOLEZAL; Tana TUZOVA; Karolina HURDALKOVA; Magda BARINOVA a Jana SKŘIČKOVÁ. Real-life Effectiveness of Afatinib Versus Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study. Anticancer Research. Athens: International Institute of Anticancer Research, 2021, roč. 41, č. 4, s. 2059-2065. ISSN 0250-7005. Dostupné z: https://doi.org/10.21873/anticanres.14975.

@article{1772601,
   author = {Svaton, Martin and Bratová, Monika and Fischer, Ondrej and Krejci, Jana and Koubkova, Leona and Cernovska, Marketa and Hrnciarik, Michal and Zemanova, Milada and Čoupková, Helena and Porzer, Bedrich and Dolezal, Daniel and Tuzova, Tana and Hurdalkova, Karolina and Barinova, Magda and Skřičková, Jana},
   article_location = {Athens},
   article_number = {4},
   doi = {https://doi.org/10.21873/anticanres.14975},
   keywords = {Afatinib; gefitinib; NSCLC; real world data},
   language = {eng},
   issn = {0250-7005},
   journal = {Anticancer Research},
   title = {Real-life Effectiveness of Afatinib Versus Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study},
   url = {https://ar.iiarjournals.org/content/41/4/2059},
   volume = {41},
   year = {2021}
}

TY  - JOUR
ID  - 1772601
AU  - Svaton, Martin - Bratová, Monika - Fischer, Ondrej - Krejci, Jana - Koubkova, Leona - Cernovska, Marketa - Hrnciarik, Michal - Zemanova, Milada - Čoupková, Helena - Porzer, Bedrich - Dolezal, Daniel - Tuzova, Tana - Hurdalkova, Karolina - Barinova, Magda - Skřičková, Jana
PY  - 2021
TI  - Real-life Effectiveness of Afatinib Versus Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study
JF  - Anticancer Research
VL  - 41
IS  - 4
SP  - 2059-2065
EP  - 2059-2065
PB  - International Institute of Anticancer Research
SN  - 02507005
KW  - Afatinib
KW  - gefitinib
KW  - NSCLC
KW  - real world data
UR  - https://ar.iiarjournals.org/content/41/4/2059
N2  - Background/Aim: We investigated efficacy differences for afatinib versus gefitinib in non-small-cell lung cancer (NSCLC) according to epidermal growth factor receptor (EGFR) mutations. Patients and Methods: We retrospectively analysed data for 343 patients with NSCLC with performance status 1 having EGFR mutations treated with gefitinib or afatinib. Overall response rate (ORR) was tested by Fisher & rsquo;s exact test. Overall (OS) and progression free (PFS) survival were estimated by Kaplan & ndash;Meier method. Results: ORR did not differ in any group or subgroup. Among all patients, we observed significantly longer PFS for those treated with afatinib vs. gefitinib (median 13.4 vs. 9.5 months, p=0.026), but only a nonsignificant trend was observed for OS. We showed nonsignificant trends of better PFS and OS using afatinib for exon 19 deletion and L858R subgroups. We observed no significant PFS differences for other EGFR mutations but a nonsignificant trend towards better OS for those treated with afatinib. Conclusion: Afatinib led to longer PFS for patients with common EGFR mutations but not for those with rare mutations.
ER  -

SVATON, Martin; Monika BRATOVÁ; Ondrej FISCHER; Jana KREJCI; Leona KOUBKOVA; Marketa CERNOVSKA; Michal HRNCIARIK; Milada ZEMANOVA; Helena ČOUPKOVÁ; Bedrich PORZER; Daniel DOLEZAL; Tana TUZOVA; Karolina HURDALKOVA; Magda BARINOVA a Jana SKŘIČKOVÁ. Real-life Effectiveness of Afatinib Versus Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study. \textit{Anticancer Research}. Athens: International Institute of Anticancer Research, 2021, roč.~41, č.~4, s.~2059-2065. ISSN~0250-7005. Dostupné z: https://doi.org/10.21873/anticanres.14975.

Přehled o publikaci